Osteoarthritis and Cartilage
Volume 18, Issue 3 , Pages 279-288, March 2010

MAPKs are essential upstream signaling pathways in proteolytic cartilage degradation – divergence in pathways leading to aggrecanase and MMP-mediated articular cartilage degradation

  • B.-C. Sondergaard

      Affiliations

    • Nordic Bioscience A/S, Herlev, Denmark
    • Corresponding Author InformationAddress correspondence and reprint requests to: Bodil-Cecilie Søndergaard, Nordic Bioscience, Herlev Hovedgade 207, DK-2730 Herlev, Denmark. Tel: 45-44-52-52-18; Fax: 45-44-52-52-51.
  • ,
  • N. Schultz

      Affiliations

    • Nordic Bioscience A/S, Herlev, Denmark
  • ,
  • S.H. Madsen

      Affiliations

    • Nordic Bioscience A/S, Herlev, Denmark
  • ,
  • A.-C. Bay-Jensen

      Affiliations

    • Nordic Bioscience A/S, Herlev, Denmark
  • ,
  • M. Kassem

      Affiliations

    • Department of Endocrinology, University of Southern Denmark, Odense, Denmark
  • ,
  • M.A. Karsdal

      Affiliations

    • Nordic Bioscience A/S, Herlev, Denmark

Received 4 June 2009; accepted 4 November 2009. published online 04 December 2009.

Summary 

Objectives

Matrix metalloproteinases (MMPs) and aggrecanases are essential players in cartilage degradation. However, the signaling pathways that results in MMP and/or aggrecanase synthesis and activation are not well understood. We investigated the molecular events leading to MMP- and aggrecanase-mediated cartilage degradation.

Methods

Cartilage degradation was induced in bovine articular cartilage explants by oncostatin M (OSM) and tumor necrosis factor (TNF), in the presence or absence of specific inhibitors of the mitogen-activated protein kinases (MAPKs) P38, P44/42 and Src family. Toxicity was followed by the AlamarBlue colorimetric assay. MMP-activity was assessed using a fluorescent substrate assay and MMP-9 and -2 activities by gelatinase zymography. MMP-mediated collagen type II degradation and MMP as well as aggrecanase-mediated aggrecan degradation was investigated with specific ELISA and hydroxyproline release by standard methods. The findings were verified by immunohistochemistry and histology.

Results

Stimulation of cartilage degradation by OSM+TNF resulted in 100-fold induction of CTX-II release (P<0.01). This was dose-dependently inhibited by MAPK P38 inhibitors and by the MAPK P44/42 inhibitors. MMP-activity and expression was significantly decreased, as evaluated by cleavage of fluorescence MMP-substrate and zymography. Immunohistochemistry confirmed these findings. Interestingly, only the P44/42 inhibitors abrogated aggrecanase-mediated aggrecan degradation.

Conclusion

We found that inhibition of MAPK P38, P44/42 and Src family abrogated proteolytic cartilage degradation by blocking MMP synthesis and activity. However, only MAPK P44/42 was essential for aggrecanase-mediated aggrecan degradation. These data suggest that various aspects of cartilage degradation can be targeted independently by inhibiting specific upstream signaling pathway.

Key words: Articular cartilage, Cartilage degradation, Catabolic enzymes, Cell signaling pathways, Matrixmetalloprotinase, Aggrecanase, Osteoarthritis, Cartilage metabolism, Enzyme pathways, Mitogen-activated protein kinases (MAPKs)

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1063-4584(09)00297-0

doi:10.1016/j.joca.2009.11.005

Osteoarthritis and Cartilage
Volume 18, Issue 3 , Pages 279-288, March 2010